

accelerating biomedical innovation



The Munich Bio-Pharma and Health Cluster:

A hotspot of innovations for the development of therapeutics and diagnostics,
with a special focus on personalized medicine, immunotherapy, and e-health

Bio^M / Tsukuba / Kawasaki Life Science Biz Meet

June 8, 2021

Horst Domdey


Munich's Life Science Research Institutes



Munich has Germany's largest life science research campus with world-renowned research institutes like

- Max Planck Institutes
- Fraunhofer Institutes
- Helmholtz Center for Environmental Health
incl. Helmholtz Artificial Intelligence Cooperation Unit (HAICU),
- Ludwig Maximilian University + University Hospital
- Technical University + University Hospital
- All 6 German Centers for Health Research
. . . in close proximity to each other.



Number of Companies







Drug Pipeline (SMEs only)



Number of Projects by Phase and Indication



- Oncology
- Infectious Diseases
- Autoimmune Diseases
- CNS Diseases
- Cardiovascular Diseases
- Other



Marketed Drugs
(derived from SMEs)



The Munich Biotech Cluster after 23 years



- top academic science at LMU, TUM, KUM, MRI, MPI, HMGU
- biotech companies: 1997: 30 2020: > 240
- employees in biotech: 1997: 2,500 2020: > 16,000
- ongoing clinical trials: 1997: 0 2020: > 130
- approved drugs: 1997: 0 2020: 12


(derived from Munich based biotech SMEs)

- > € 5 bn private investments in SME
- > € 2 bn investments in infrastructure
- Bio^M support since 1997
- a top location, with a dynamic and experienced network of (serial) entrepreneurs, investors and innovators



Bavarian Biotech – International Connections

Bio M



What makes Munich's biotech industry unique?

Munich's biotech industry excels by its diversity and its special focus on

- P4 medicine

Leading Edge Cluster Program m⁴ & DigiMed Bayern

- Drug development

12 drugs on the market (incl. 2 block busters)


> 130 drug candidates currently in clinical trials

- ATMPs

ethris, Freeline, Medigene, Minaris, Sirion, ViGeneron

- Diagnostics development

fast and reliable test systems for bacterial and viral infections





- duration: Q4 2018 to Q4 2023.
- scientific lead: DHM
- coordination: Bio^M
- funding (Euro 22.5 Mio.) by the Bavarian Ministry of Health

goals

- collect genomic, proteomic and metabolomic data of thousands of patients suffering from atherosclerosis
- include diagnostic data, therapy decision and outcome
- use the complete data set (“big data”) for better therapy decisions in the future



Bayerisches Staatsministerium für
Gesundheit und Pflege



... and what else?

